CN110742924B - A kind of Chinese medicine volatile oil composition and application thereof - Google Patents
A kind of Chinese medicine volatile oil composition and application thereof Download PDFInfo
- Publication number
- CN110742924B CN110742924B CN201911063794.5A CN201911063794A CN110742924B CN 110742924 B CN110742924 B CN 110742924B CN 201911063794 A CN201911063794 A CN 201911063794A CN 110742924 B CN110742924 B CN 110742924B
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- parts
- composition
- chinese medicine
- borneol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 21
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 21
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 20
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 20
- 229940116229 borneol Drugs 0.000 claims abstract description 20
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 244000136948 Ocimum sanctum Species 0.000 claims description 28
- 235000004072 Ocimum sanctum Nutrition 0.000 claims description 28
- 239000000645 desinfectant Substances 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 9
- 238000000222 aromatherapy Methods 0.000 claims description 5
- 239000007923 nasal drop Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 abstract description 13
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 235000016477 Taralea oppositifolia Nutrition 0.000 abstract 1
- 241001358109 Taralea oppositifolia Species 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 8
- 229940027941 immunoglobulin g Drugs 0.000 description 7
- 231100001274 therapeutic index Toxicity 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000628997 Flos Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001256 steam distillation Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241001529821 Agastache Species 0.000 description 3
- 208000005156 Dehydration Diseases 0.000 description 3
- 241001571736 Lysimachia foenum-graecum Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 2
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/06—Oxygen or sulfur directly attached to a cycloaliphatic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Agronomy & Crop Science (AREA)
- Virology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pulmonology (AREA)
- Pest Control & Pesticides (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种中药挥发油组合物及其应用，由以下重量配比的原料药制成：零陵香挥发油1～35份、广藿香挥发油1～15份、野菊花挥发油1～15份和冰片1～5份。该组合物以零陵香挥发油为主要原料，配合加入广藿香挥发油、野菊花挥发油以及冰片等芳香化湿药物，各组分产生协同增效作用，经体外抗病毒药效学实验证明，本发明组合物能够预防和抑制流感病毒引起的感冒。The invention relates to a traditional Chinese medicine volatile oil composition and an application thereof. Borneol 1 to 5 servings. The composition uses the volatile oil of tonka as the main raw material, and is combined with the aromatic and moisturizing drugs such as patchouli volatile oil, wild chrysanthemum volatile oil and borneol, and each component has a synergistic effect. The inventive composition can prevent and inhibit cold caused by influenza virus.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine volatile oil composition and application thereof in medicines for preventing and inhibiting influenza caused by influenza viruses.
Background
Influenza is an acute respiratory infectious disease caused by influenza virus, and has the characteristics of rapid spread and wide spread range. Influenza a i (H1N 1) has caused a worldwide pandemic since 1918 in spanish outbreaks, and particularly in 2009 influenza a i has caused a great economic loss as well as a serious threat to human health. In recent years, the spread of highly pathogenic avian influenza in humans has led to an increase in the number of infectious and dead people due to the variation of influenza virus antigens. In the high-incidence stage of influenza, the most effective prevention method is to prevent and treat the spread of influenza virus in the air, and isolation and space environment disinfection are well performed to avoid secondary spread. Common air disinfection methods include chemical reagent methods such as peracetic acid, hydrogen peroxide, formaldehyde, 84 disinfectant, and the like, and physical methods such as ultraviolet irradiation, ozone generators, and the like. Although these methods can kill pathogenic microorganisms or viruses in the air, have rapid action and low effective concentration, they have certain defects, such as toxicity, irritation, metal corrosivity and poor sustained effect; many of the pollutants form pollutants, influence human health to different degrees and are not suitable for the environment of people; all personnel must leave the field during disinfection, and the operating system needs protective measures; the peculiar smell can not be eliminated quickly after the disinfection, and the long-term use of the disinfectant can cause the danger of accumulation and poisoning of human bodies. Therefore, the research on a safe and effective air disinfectant is of great significance.
Infectious diseases caused by pathogenic bacteria or viruses transmitted through the air belong to the category of warm diseases in traditional Chinese medicine, and the treatment medicine mainly comprises two traditional Chinese medicines of clearing heat and removing toxicity and eliminating dampness with aromatics. Lysimachia foenum-graecum, also known as Lysimachia foenum-graecum, lavender, and holy basil, are dried aerial herbs of Lysimachia foenum-graecum Hance, which are commonly used as spices. The herba Lysimachiae foenumgraeci contains a large amount of volatile oil, coumarin, etc., and has effects of dispelling pathogenic wind cold, removing filth, treating seasonal pathogens of common cold headache, upper qi lumbago, chest distress, abdominal distention, spermatorrhea, ascarid expelling, etc. At present, the prior art is mostly a research on an extraction method of the effective components of holy basil, and no literature report on the application of holy basil to air disinfectants is found.
Disclosure of Invention
In view of the above, the primary objective of the present invention is to provide a Chinese medicine volatile oil composition, which has the function of in vitro influenza virus inhibition and the function of mucosal immunity stimulation, thereby preventing and inhibiting the cold caused by influenza virus.
The technical scheme for realizing the aim of the invention is as follows:
a traditional Chinese medicine volatile oil composition is prepared from the following raw material medicines in parts by weight: 1-35 parts of holy basil volatile oil, 1-15 parts of patchouli volatile oil, 1-15 parts of wild chrysanthemum flower volatile oil and 1-5 parts of borneol.
Preferably, the weight ratio of each raw material medicine of the invention is as follows: 5-20 parts of holy basil volatile oil, 3-6 parts of patchouli volatile oil, 3-6 parts of wild chrysanthemum flower volatile oil and 1-3 parts of borneol,
preferably, the weight ratio of each raw material medicine is as follows: 10 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum flower volatile oil and 1 part of borneol.
The volatile oil of holy basil, the volatile oil of patchouli and the volatile oil of wild chrysanthemum can be extracted and prepared from related plants by a steam distillation method, a water diffusion steam distillation method, a solvent extraction method, a carbon dioxide supercritical extraction method and the like.
The composition takes the volatile oil of holy basil as a monarch drug, and has the effects of eliminating dampness and avoiding dirty with aromatics; the patchouli volatile oil is a ministerial drug, has the efficacy of eliminating dampness by fragrance, and has better efficacy when used with a monarch drug; the volatile oil of flos Chrysanthemi Indici is used as adjuvant drug, has effects of clearing heat and detoxicating, and can be used for adjuvant treatment of febrile disease and fever; borneol is a guiding drug and has the functions of inducing resuscitation by fragrance and promoting the ascending of drugs. The raw materials are combined together, and have synergistic effect, and the in vitro antiviral pharmacodynamics experiment and the in vivo mucosa stimulating immunity experiment prove that the composition can prevent and inhibit the cold caused by the influenza virus.
The invention also aims to provide application of the traditional Chinese medicine volatile oil composition in preparing a medicine for preventing or treating cold caused by influenza. The Chinese medicinal volatile oil composition is used as an effective component, pharmaceutically acceptable auxiliary materials such as preservatives, emulsifiers, humectants, thickeners and the like are added, and the Chinese medicinal volatile oil composition is prepared into dosage forms such as air disinfectants, aromatherapy essential oil, smokeless aromatherapy, massage cream or nasal drops and the like according to the conventional technical means in the field.
The invention also provides an air disinfectant, which takes the traditional Chinese medicine volatile oil composition as an active ingredient, and the auxiliary materials can be added with a proper amount of emulsifier such as Tween-80 and then diluted by a proper amount of deionized water, so that the preparation method is simple and easy. The air disinfectant disclosed by the invention takes four natural plant components of holy basil, cablin potchouli herb, wild chrysanthemum flower and borneol as raw materials, does not contain other chemical components, and does not bring any negative influence on the environment and the health of human bodies on the basis of preventing and inhibiting cold caused by influenza virus.
Compared with the prior art, the invention has the following beneficial effects:
the composition disclosed by the invention has the advantages that the holy basil volatile oil is taken as a main raw material, and aromatic dampness-resolving medicines such as the patchouli volatile oil, the wild chrysanthemum volatile oil and the borneol are added in a matching manner, so that the components generate a synergistic interaction effect, pharmacodynamic studies show that the composition has the effects of inhibiting and preventing influenza viruses in vitro on one hand, and can effectively induce mucosal immunoreaction in vivo by nasal drip or atomization administration on the other hand, so that a large amount of s-IgA antibodies with a cross protection effect are generated to cause the mucosal immunoreaction, and the composition has a better antiviral effect, is better than the single holy basil volatile oil and a traditional Chinese medicine control group (combination of the patchouli volatile oil, the wild chrysanthemum volatile oil and the borneol) in the aspects of inhibiting the viruses and improving the mucosal immunity of mice, and can be applied to preventing and.
Detailed Description
The present invention is further illustrated by the following specific embodiments, which are not intended to limit the scope of the invention.
Preparing the volatile oil of holy basil: taking 2.0kg of dried holy basil, adding 10 times of water, soaking for 30 minutes, carrying out ultrasonic treatment (70 kHz) for 30 minutes, heating, collecting water vapor, and condensing the water vapor to obtain an oil-water separation part. Collecting the upper layer volatile oil, and adding anhydrous sodium sulfate for dehydration treatment to obtain herba Lysimachiae Foenumgraeci volatile oil.
Preparing patchouli volatile oil: taking 1.0kg of dried cablin potchouli herb, adding 8 times of water, soaking for 40 minutes, carrying out ultrasonic treatment (60 kHz) for 40 minutes, heating, collecting water vapor, and condensing the water vapor to obtain an oil-water separation part. Collecting the upper layer volatile oil, and adding anhydrous sodium sulfate for dehydration treatment to obtain herba Agastaches volatile oil.
Preparing wild chrysanthemum volatile oil: taking 1.0kg of dried wild chrysanthemum, adding 9 times of water, soaking for 30 minutes, carrying out ultrasonic treatment (80 kHz) for 45 minutes, heating, collecting water vapor, and condensing the water vapor to obtain an oil-water separation part. Collecting the upper layer volatile oil, and adding anhydrous sodium sulfate for dehydration treatment to obtain flos Chrysanthemi Indici volatile oil.
Example 1: air disinfectant
Mixing and dissolving 30 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum volatile oil and 1 part of borneol, adding a proper amount of Tween 80 serving as an emulsifier, adding deionized water to dilute the mixture to 1000 times, and uniformly mixing the mixture to obtain the external ointment.
Example 2: aromatherapy essential oil
Mixing and dissolving 10 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum flower volatile oil and 1 part of borneol.
Example 3: smokeless champignon
Mixing and dissolving 20 parts of holy basil volatile oil, 8 parts of patchouli volatile oil, 8 parts of wild chrysanthemum volatile oil and 1 part of borneol, and adding a proper amount of isododecane for dissolving and diluting to 1000 times.
Example 4: massage cream
Mixing and dissolving 15 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum volatile oil and 1 part of borneol, adding a proper amount of vaseline, diluting to 100 times, and mixing.
Example 5: nose drops
Mixing and dissolving 15 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum volatile oil and 1 part of borneol, adding a proper amount of tween 80 serving as an emulsifier, a proper amount of sodium benzoate serving as a preservative, adding a proper amount of deionized water to dilute to 100 times, and mixing and dissolving to obtain the traditional Chinese medicine.
The invention takes the prevention of influenza from traditional Chinese medicine as an entry point, adopts holy basil volatile oil as a main raw material according to pharmacodynamic screening, and adds aromatic dampness-resolving medicines such as patchouli volatile oil, wild chrysanthemum volatile oil, borneol and the like to perform synergistic action, thereby playing a role in preventing cold caused by influenza. The technical effect of the invention is proved by in vitro cell antivirus experiment and in vivo mucosa stimulating immunity experiment.
In-vitro prevention and inhibition of influenza virus
1 materials of the experiment
1.1 test drugs
The Chinese medicinal volatile oil composition (prepared according to the method of example 2) is prepared; herba Lysimachiae foenumgraeci volatile oil group (extracted by steam distillation), and Chinese medicinal control group (herba Agastaches volatile oil, flos Chrysanthemi Indici volatile oil, and Borneolum Syntheticum at mass ratio of 5: 1); positive control drug: ribavirin (Chenxin pharmaceutical Co., Ltd.).
1.2 strains and cells
Influenza A I virus FM1 mouse lung adapted strain (institute of medical and biotechnology, national academy of medical sciences), and dry dog kidney cell (MDCK) passage, and its titer is judged by cytopathy and hemagglutination of chicken erythrocyte.
2 experimental methods and results
2.1 half cell Toxic Concentration (TC)50) Screening
After the cells grew into a monolayer, 8 different concentrations of drug (1000, 500, 250, 125, 62.50, 31.25, 15.63, 7.82) were added in multiple dilutions, μ g.mL-1Each concentration is 4 multi-well cells, a normal cell control and a positive drug ribavirin control are set, the temperature is 37 ℃, and the CO content is 5 percent2The experiment was terminated after 4d incubation. The morphological change of the cells is observed every day in the experiment, and finally, the half Toxicity Concentration (TC) of the medicine is detected by a thiazole blue staining method (MTT method)50) Obtaining TC of each group of drugs50And (6) obtaining the result.
2.2 direct inhibition of viruses
Inoculating to 96-well culture plate, observing cytopathy in normal control group, determining cell survival amount by determining OD value by MTT method when cytopathy reaches +++ in virus control group, and calculating concentration (IC) of each group of drugs for inhibiting 50% cytopathy caused by virus by Reed-Muench method50) And antiviral Therapeutic Index (TI). The TI value is a comprehensive judgment index of the curative effect of the treatment medicament, and the larger the value is, the smaller the toxicity of the medicament is, and the lower the effective concentration for inhibiting the virus is.
3 results
Determination of TC for each group of drugs50The results are shown in Table 1, TC for the pharmaceutical combination of the invention50250 μ g.mL of-1(ii) a Holy basil group TC50Is 500. mu.g.mL-1(ii) a Traditional Chinese medicine control group TC50125. mu.g.mL-1(ii) a Positive drug ribavirin group TC50Is 1000. mu.g.mL-1。
Determination of IC for each group of drugs50The results are shown in Table 1, the median inhibitory concentration IC of the combinations of the invention5023.91. mu.g.mL-1Corresponding to a Therapeutic Index (TI) of 10.46; holy basil incense group IC5055.82. mu.g.mL-1TI is 8.96; median inhibitory concentration IC of control group of Chinese herbs5035.29. mu.g.mL-1TI is 3.54; median inhibitory concentration IC of positive drug ribavirin5032.53. mu.g.mL-1And TI was 30.74.
Except for the positive control group, the TI value of the composition group is the highest in the inhibiting effect on FM1, and the inhibiting effect of the composition on FM1 virus is proved to be better than that of the single holy basil volatile oil group or the traditional Chinese medicine control group. The results show that compared with the single volatile oil of holy basil and the traditional Chinese medicine control group (the mass of the volatile oil of patchouli, the volatile oil of wild chrysanthemum and the borneol is 5: 1), the pharmaceutical composition has lower toxicity to cells and stronger therapeutic action to viruses.
TABLE 1 MTT method for determining the toxic effect of drugs on MDCK cells and the inhibitory effect on FM 1: (n = 4）
Second, stimulation of mucosal immune function in vivo
1 experimental materials:
compositions of the invention (prepared as in example 2); herba Lysimachiae foenumgraeci volatile oil group (extracted by steam distillation), and Chinese medicinal control group (herba Agastaches volatile oil, flos Chrysanthemi Indici volatile oil, and Borneolum Syntheticum at mass ratio of 5: 1); positive control drug: ribavirin (Chenxin pharmaceutical Co., Ltd.).
Strains and cells: influenza A I virus FM1 mouse lung adapted strain (institute of medical and biotechnology, national academy of medical sciences).
Experimental animals: 50 SPF-grade BABL/c mice, female, with a mass of 13-15 g (Guangdong province center for laboratory animals).
Reagent: mouse secretory immunoglobulin A (s-IgA) enzyme linked immunosorbent assay kit; mouse immunoglobulin G (IgG) enzyme linked immunosorbent assay kit.
2 experimental methods and results:
2.1 animal grouping and administration
The BABL/c mice were randomly divided into 5 groups of 10 mice each, namely a normal control group, a placebo group, a combined nasal drop group of the invention and a combined nebulized group of the invention. The drug is taken for prevention 7 days in advance, 1mL of normal saline is taken for the placebo group by intragastric administration every day, 0.05mL of the composition is taken for atomization every day by adopting an ultrasonic atomizer, and the normal control group is normally fed. After 7 days of continuous administration, mice were lightly anesthetized with ether and sacrificed at 5 sesqui-lethal dose (5 LD)50) Influenza virus 50. mu.L of nasal-drop infected mice, followed by continuous observation for 5 days, the mice were sacrificed and samples were collected.
2.2 serum IgA, IgG detection
Removing eyeballs from mice, collecting blood, standing the blood at room temperature for 30min, centrifuging at 2000r/min for 20min, collecting serum, storing at-20 ℃, and measuring IgA and IgG in the serum according to the method of the kit specification.
2.3 alveolar lavage fluid and nasal mucosa s-IgA detection
After the mice were sacrificed, the trachea was separated, sterile physiological saline was injected from the upper end of the trachea to the lung tissue with a needle tube, the washing solution was withdrawn, 2 mL each time, and the alveolar lavage fluid was collected by washing 2 times. The same method is used to inject normal saline from trachea to nose and collect nasal mucosa washing liquid. Determination of alveolar lavage fluid and nasal mucosal irrigation fluidρs-IgA content.
3 results
As shown in Table 2, compared with the placebo group, the composition of the invention can obviously improve the content of lavage fluid s-IgA, serum IgA and IgG, and the difference has statistical significance: (P<0.05 orP<0.01). The composition group has the highest effect of increasing the content of IgA, IgG and s-IgA of mice, and the effect of improving the mucosal immunity of the mice of the composition group is proved to be better than that of a single holy basil group or a traditional Chinese medicine control group.
TABLE 2 Effect of the Combined essential oils of the invention on IgA, IgG, s-IgA content: (n = 10）
*P<0.05，**P<0.01, compared to placebo.
The results show that the holy basil volatile oil is used as the main raw material and is matched with the patchouli volatile oil, the wild chrysanthemum volatile oil and the borneol, compared with the single holy basil volatile oil and a traditional Chinese medicine control group (the combination of the patchouli volatile oil, the wild chrysanthemum volatile oil and the borneol), the combination of the raw materials generates a synergistic interaction effect, and the in vitro antiviral pharmacodynamics experiment and the in vivo mucosa stimulating immunity experiment prove that the composition can play a role in preventing and inhibiting the cold caused by influenza virus.
Claims (5)
1. The traditional Chinese medicine volatile oil composition is characterized in that active ingredients of the composition are prepared from the following raw material medicines in parts by weight: 5-20 parts of holy basil volatile oil, 3-6 parts of patchouli volatile oil, 3-6 parts of wild chrysanthemum flower volatile oil and 1-3 parts of borneol.
2. The traditional Chinese medicine volatile oil composition of claim 1, wherein the weight ratio of each raw material medicine is as follows: 10 parts of holy basil volatile oil, 5 parts of patchouli volatile oil, 5 parts of wild chrysanthemum flower volatile oil and 1 part of borneol.
3. The use of the Chinese medicinal volatile oil composition according to any one of claims 1 to 2 in the preparation of a medicament for preventing or treating influenza.
4. Use according to claim 3, characterized in that: the dosage form of the medicine is air disinfectant, aromatherapy essential oil, smokeless aromatherapy, massage cream or nasal drop.
5. An air disinfectant comprising the Chinese medicinal volatile oil composition of any one of claims 1-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911063794.5A CN110742924B (en) | 2019-11-04 | 2019-11-04 | A kind of Chinese medicine volatile oil composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911063794.5A CN110742924B (en) | 2019-11-04 | 2019-11-04 | A kind of Chinese medicine volatile oil composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110742924A CN110742924A (en) | 2020-02-04 |
| CN110742924B true CN110742924B (en) | 2021-07-16 |
Family
ID=69281942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911063794.5A Active CN110742924B (en) | 2019-11-04 | 2019-11-04 | A kind of Chinese medicine volatile oil composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110742924B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796435B (en) * | 2022-05-11 | 2023-05-12 | 澳门科技大学 | Drug composition for mouth and nose with anti-SARS-CoV-2 virus effect and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361941A (en) * | 2008-09-28 | 2009-02-11 | 东莞广州中医药大学中医药数理工程研究院 | Pharmaceutical composition for preventing and treating cold and preparation method thereof |
| CN102349991A (en) * | 2011-05-29 | 2012-02-15 | 王红芳 | Composition for killing virus and preventing influenza and cold prevention plaster prepared by composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413675A (en) * | 2002-08-28 | 2003-04-30 | 李家文 | Hollow multifunction incense and its preparation method and using method |
| CN107137549A (en) * | 2017-05-23 | 2017-09-08 | 郑州市中医院 | One kind dehumidifying inducing diaphoresis sachet and preparation method thereof |
-
2019
- 2019-11-04 CN CN201911063794.5A patent/CN110742924B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361941A (en) * | 2008-09-28 | 2009-02-11 | 东莞广州中医药大学中医药数理工程研究院 | Pharmaceutical composition for preventing and treating cold and preparation method thereof |
| CN102349991A (en) * | 2011-05-29 | 2012-02-15 | 王红芳 | Composition for killing virus and preventing influenza and cold prevention plaster prepared by composition |
Non-Patent Citations (2)
| Title |
|---|
| Optimising chitosan-pectin hydrogel beads containing combined garlic and holy basil essential oils and their application as antimicrobial inhibitor;Kittikoon Torpol等;《International Journal of Food Science + Technology》;20190203;第2064-2074页 * |
| 灵香草挥发油成分研究;周银珍等;《广东化工》;19851231(第04期);第27-29页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110742924A (en) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106538638B (en) | A kind of Chinese medicine antiseptic and preparation method thereof | |
| WO2014023145A1 (en) | Mite killing bactericide and method for preparing same | |
| CN102341114A (en) | Herbal extract composition for prevention and treatment of influenza | |
| CN102512490A (en) | Aromatherapy essential oil for treating gynecological inflammation and essential oil aromatherapy patch | |
| Malabadi et al. | Role of botanical essential oils as a therapy for controlling coronavirus (SARS-CoV-2) disease (Covid-19) | |
| Abbass | Eucalyptus essential oil; an off-label use to protect the world from COVID-19 pandemic: Review-based hypotheses | |
| CN114246925A (en) | Traditional Chinese medicine essential oil and application thereof | |
| KR20030019097A (en) | Compositions for treatment and prevention of cold having antiviral activity | |
| CN110742924B (en) | A kind of Chinese medicine volatile oil composition and application thereof | |
| WO2014019486A1 (en) | New application of patchouli oil | |
| CN108371191A (en) | A kind of air antiseptic and its preparation method and application | |
| CN100444734C (en) | A compound antivirus sprayer and preparation method thereof | |
| CN113171393A (en) | Traditional Chinese medicine composition for preventing influenza, preparation method and traditional Chinese medicine slow-release sachet | |
| CN101796970A (en) | Sterilizing antiviral influenza-preventing spraying agent prepared from traditional Chinese medicine and production method thereof | |
| CN104491121B (en) | It is a kind of to be used to treat antibacterial Essence of breathing problem and preparation method thereof | |
| CN101664441B (en) | A kind of traditional Chinese medicine composition containing Folium Folium and its application | |
| CN106729070A (en) | A kind of external application energy gauging for mitigating arthralgia and preparation method thereof | |
| CN102198192B (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
| CN105726742A (en) | Anti-neweastle disease virus and anti-avian influenza veterinary herbal medicine and preparation method thereof | |
| US20060003030A1 (en) | Essential oils for treating and/ or preventing allergic disease | |
| KR101177182B1 (en) | Artemisia Pill Contained with the Artemisia Alcoholic Extract Killing the 2009AH1N1 Influenza Viruses and the H9N2 Avian Influenza Viruses | |
| CN101104065A (en) | A traditional Chinese medicine preparation and preparation method for preventing respiratory viral infectious diseases | |
| Ali et al. | Inhibit of the Virus Infections by using Aromatic Oils, Saccharomyces cerevisiae, Boswellia Carterii and Zinc. | |
| CN111012823A (en) | Medicine containing lindera glauca volatile oil and administration method thereof | |
| CN104800422A (en) | Tea tree essential oil for treating groin tinea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |